Share Price and Basic Stock Data
Last Updated: January 27, 2026, 9:24 pm
| PEG Ratio | 3.14 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Sharda Cropchem Ltd, operating in the agrochemicals and pesticides sector, reported a market capitalization of ₹7,257 Cr and a stock price of ₹803. The company’s sales rose to ₹4,045 Cr for the year ending March 2023, up from ₹3,580 Cr in the previous fiscal year. The trailing twelve months (TTM) revenue stood at ₹4,672 Cr. Quarterly sales fluctuated significantly, with the highest quarterly sales of ₹1,482 Cr recorded in March 2023, followed by a dip to ₹581 Cr in September 2023, illustrating seasonality in the business. The company’s operating profit margin (OPM) for FY 2025 is expected to be around 14%, indicating a competitive position within the agrochemical sector. This performance reflects Sharda’s ability to capitalize on the growing demand for crop protection products, despite challenges such as fluctuating raw material prices and changing regulatory environments.
Profitability and Efficiency Metrics
Sharda Cropchem’s profitability metrics showcase a mixed performance. The net profit for the year ending March 2023 was ₹342 Cr, slightly down from ₹349 Cr in FY 2022, resulting in an earnings per share (EPS) of ₹37.90. However, the company reported a notable decline in profitability in the subsequent quarters, with a net loss of ₹89 Cr in June 2023. The return on equity (ROE) stood at 12.6%, while the return on capital employed (ROCE) was reported at 16.5%. The interest coverage ratio (ICR) of 311.10x indicates an exceptionally strong ability to meet interest obligations, reflecting minimal debt burdens, with total borrowings at just ₹4 Cr. The cash conversion cycle (CCC) of 124 days suggests a reasonable efficiency in managing working capital, although the inventory turnover ratio of 4.40x indicates room for improvement compared to typical sector benchmarks.
Balance Sheet Strength and Financial Ratios
Sharda Cropchem’s balance sheet exhibits robust financial health with total assets amounting to ₹4,713 Cr and total liabilities of ₹4,028 Cr, yielding a debt-to-equity ratio of 0.00, reflecting a strong equity position with minimal leverage. The company has reserves of ₹2,585 Cr, which underpins its capacity for future investments and growth initiatives. The book value per share increased to ₹277.16 in March 2025, affirming the company’s inherent value. Financial ratios such as the current ratio at 1.81x and quick ratio at 1.32x indicate a solid liquidity position, allowing Sharda to easily cover short-term liabilities. However, the return on assets (ROA) of 6.44% suggests opportunities for enhancing asset efficiency, particularly in asset utilization and revenue generation.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Sharda Cropchem reveals a strong promoter holding of 74.82%, indicating significant management control and alignment with shareholder interests. The presence of foreign institutional investors (FIIs) increased from 2.41% in December 2022 to 5.26% as of September 2025, reflecting growing confidence among international investors. Domestic institutional investors (DIIs) held a stable 9.26% as of September 2025. The total number of shareholders rose to 67,290, indicating increasing retail investor participation. This diverse ownership structure, with a substantial promoter stake coupled with growing institutional interest, points towards robust investor confidence in the company’s long-term growth prospects. However, the volatility in net profit and sales could pose concerns among risk-averse investors.
Outlook, Risks, and Final Insight
Looking ahead, Sharda Cropchem is well-positioned to benefit from the increasing demand for agrochemical products driven by rising agricultural productivity needs. However, risks such as fluctuations in raw material prices, regulatory changes, and market competition could impact profitability and operational efficiency. The company’s low debt levels and high interest coverage provide a cushion against economic downturns, enhancing financial stability. If Sharda can improve its operating margins and maintain revenue growth, it could solidify its market position further. Conversely, failure to navigate regulatory challenges or manage costs effectively may hinder its growth trajectory. Overall, Sharda’s strong fundamentals and market positioning suggest potential for continued growth, albeit with caution regarding external market dynamics.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Epigral Ltd | 4,555 Cr. | 1,056 | 2,114/1,045 | 11.3 | 487 | 0.57 % | 24.9 % | 22.3 % | 10.0 |
| Dharmaj Crop Guard Ltd | 730 Cr. | 216 | 391/165 | 15.0 | 131 | 0.00 % | 12.0 % | 9.28 % | 10.0 |
| Bhaskar Agrochemicals Ltd | 54.4 Cr. | 104 | 149/56.6 | 9.75 | 40.0 | 0.00 % | 21.3 % | 24.7 % | 10.0 |
| Bhagiradha Chemicals & Industries Ltd | 2,604 Cr. | 203 | 331/198 | 98.3 | 54.9 | 0.07 % | 7.44 % | 4.91 % | 1.00 |
| Best Agrolife Ltd | 775 Cr. | 22.0 | 35.8/16.3 | 60.6 | 22.8 | 0.91 % | 12.9 % | 9.95 % | 1.00 |
| Industry Average | 10,322.45 Cr | 1,043.38 | 28.82 | 369.04 | 0.46% | 15.21% | 19.87% | 6.67 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 722 | 1,017 | 1,482 | 638 | 581 | 632 | 1,312 | 785 | 777 | 929 | 1,829 | 985 | 929 |
| Expenses | 656 | 810 | 1,164 | 697 | 560 | 563 | 1,057 | 708 | 687 | 815 | 1,525 | 770 | 796 |
| Operating Profit | 65 | 207 | 318 | -59 | 21 | 69 | 255 | 77 | 90 | 115 | 303 | 215 | 133 |
| OPM % | 9% | 20% | 21% | -9% | 4% | 11% | 19% | 10% | 12% | 12% | 17% | 22% | 14% |
| Other Income | 10 | 3 | 7 | 26 | 24 | 12 | -2 | 19 | 25 | 1 | 25 | 32 | 29 |
| Interest | 0 | 1 | 2 | 1 | 5 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 |
| Depreciation | 60 | 65 | 68 | 70 | 74 | 69 | 54 | 65 | 69 | 69 | 72 | 78 | 76 |
| Profit before tax | 15 | 143 | 255 | -105 | -34 | 12 | 198 | 31 | 46 | 46 | 256 | 169 | 86 |
| Tax % | 17% | 24% | 22% | -15% | -18% | 62% | 28% | 11% | 7% | 32% | 20% | 16% | 13% |
| Net Profit | 12 | 108 | 199 | -89 | -28 | 5 | 143 | 27 | 42 | 31 | 204 | 143 | 74 |
| EPS in Rs | 1.34 | 12.01 | 22.04 | -9.82 | -3.06 | 0.51 | 15.90 | 3.02 | 4.70 | 3.45 | 22.56 | 15.83 | 8.24 |
Last Updated: December 29, 2025, 5:00 am
Below is a detailed analysis of the quarterly data for Sharda Cropchem Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 929.00 Cr.. The value appears to be declining and may need further review. It has decreased from 985.00 Cr. (Jun 2025) to 929.00 Cr., marking a decrease of 56.00 Cr..
- For Expenses, as of Sep 2025, the value is 796.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 770.00 Cr. (Jun 2025) to 796.00 Cr., marking an increase of 26.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 133.00 Cr.. The value appears to be declining and may need further review. It has decreased from 215.00 Cr. (Jun 2025) to 133.00 Cr., marking a decrease of 82.00 Cr..
- For OPM %, as of Sep 2025, the value is 14.00%. The value appears to be declining and may need further review. It has decreased from 22.00% (Jun 2025) to 14.00%, marking a decrease of 8.00%.
- For Other Income, as of Sep 2025, the value is 29.00 Cr.. The value appears to be declining and may need further review. It has decreased from 32.00 Cr. (Jun 2025) to 29.00 Cr., marking a decrease of 3.00 Cr..
- For Interest, as of Sep 2025, the value is 0.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.00 Cr. (Jun 2025) to 0.00 Cr., marking a decrease of 1.00 Cr..
- For Depreciation, as of Sep 2025, the value is 76.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 78.00 Cr. (Jun 2025) to 76.00 Cr., marking a decrease of 2.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 86.00 Cr.. The value appears to be declining and may need further review. It has decreased from 169.00 Cr. (Jun 2025) to 86.00 Cr., marking a decrease of 83.00 Cr..
- For Tax %, as of Sep 2025, the value is 13.00%. The value appears to be improving (decreasing) as expected. It has decreased from 16.00% (Jun 2025) to 13.00%, marking a decrease of 3.00%.
- For Net Profit, as of Sep 2025, the value is 74.00 Cr.. The value appears to be declining and may need further review. It has decreased from 143.00 Cr. (Jun 2025) to 74.00 Cr., marking a decrease of 69.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 8.24. The value appears to be declining and may need further review. It has decreased from 15.83 (Jun 2025) to 8.24, marking a decrease of 7.59.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:40 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 790 | 1,061 | 1,222 | 1,399 | 1,707 | 1,998 | 2,003 | 2,396 | 3,580 | 4,045 | 3,163 | 4,320 | 4,672 |
| Expenses | 630 | 878 | 941 | 1,075 | 1,343 | 1,621 | 1,653 | 1,945 | 2,884 | 3,386 | 2,860 | 3,705 | 3,906 |
| Operating Profit | 160 | 183 | 281 | 324 | 364 | 376 | 350 | 450 | 696 | 659 | 303 | 615 | 766 |
| OPM % | 20% | 17% | 23% | 23% | 21% | 19% | 17% | 19% | 19% | 16% | 10% | 14% | 16% |
| Other Income | 32 | 25 | 23 | 14 | 9 | -22 | -12 | 46 | 29 | 40 | 60 | 60 | 88 |
| Interest | 8 | 9 | 8 | 9 | 15 | 20 | 16 | 16 | 15 | 20 | 24 | 21 | 2 |
| Depreciation | 29 | 23 | 35 | 56 | 70 | 99 | 137 | 170 | 245 | 248 | 267 | 275 | 295 |
| Profit before tax | 155 | 175 | 261 | 272 | 287 | 235 | 185 | 309 | 464 | 431 | 72 | 378 | 557 |
| Tax % | 29% | 30% | 33% | 30% | 34% | 25% | 11% | 26% | 25% | 21% | 56% | 20% | |
| Net Profit | 111 | 123 | 175 | 190 | 191 | 176 | 165 | 229 | 349 | 342 | 32 | 304 | 452 |
| EPS in Rs | 12.31 | 13.63 | 19.41 | 21.11 | 21.14 | 19.55 | 18.25 | 25.40 | 38.71 | 37.90 | 3.53 | 33.74 | 50.08 |
| Dividend Payout % | 16% | 18% | 21% | 19% | 19% | 20% | 22% | 20% | 16% | 16% | 85% | 27% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 10.81% | 42.28% | 8.57% | 0.53% | -7.85% | -6.25% | 38.79% | 52.40% | -2.01% | -90.64% | 850.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | 31.47% | -33.70% | -8.05% | -8.38% | 1.60% | 45.04% | 13.61% | -54.41% | -88.64% | 940.64% |
Sharda Cropchem Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 17% |
| 3 Years: | 6% |
| TTM: | 37% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 8% |
| 3 Years: | -5% |
| TTM: | 184% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 27% |
| 3 Years: | 21% |
| 1 Year: | 65% |
| Return on Equity | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 12% |
| 3 Years: | 10% |
| Last Year: | 13% |
Last Updated: September 5, 2025, 1:26 pm
Balance Sheet
Last Updated: December 4, 2025, 1:57 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 90 | 90 | 90 | 90 | 90 | 90 | 90 | 90 | 90 | 90 | 90 | 90 | 90 |
| Reserves | 466 | 564 | 715 | 870 | 1,045 | 1,194 | 1,313 | 1,524 | 1,822 | 2,142 | 2,147 | 2,410 | 2,585 |
| Borrowings | 40 | 38 | 2 | 0 | 170 | 0 | 0 | 81 | 47 | 3 | 18 | 8 | 4 |
| Other Liabilities | 319 | 354 | 522 | 686 | 914 | 914 | 940 | 1,163 | 1,779 | 2,108 | 1,773 | 2,205 | 2,224 |
| Total Liabilities | 914 | 1,047 | 1,329 | 1,646 | 2,219 | 2,198 | 2,343 | 2,858 | 3,738 | 4,343 | 4,028 | 4,713 | 4,903 |
| Fixed Assets | 64 | 88 | 130 | 210 | 226 | 372 | 416 | 544 | 592 | 668 | 708 | 750 | 1,109 |
| CWIP | 133 | 149 | 210 | 232 | 360 | 220 | 161 | 131 | 212 | 204 | 283 | 291 | 0 |
| Investments | 174 | 95 | 90 | 61 | 22 | 212 | 116 | 83 | 134 | 32 | 159 | 294 | 555 |
| Other Assets | 542 | 715 | 899 | 1,143 | 1,611 | 1,394 | 1,650 | 2,099 | 2,800 | 3,439 | 2,878 | 3,377 | 3,240 |
| Total Assets | 914 | 1,047 | 1,329 | 1,646 | 2,219 | 2,198 | 2,343 | 2,858 | 3,738 | 4,343 | 4,028 | 4,713 | 4,903 |
Below is a detailed analysis of the balance sheet data for Sharda Cropchem Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 90.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 90.00 Cr..
- For Reserves, as of Sep 2025, the value is 2,585.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,410.00 Cr. (Mar 2025) to 2,585.00 Cr., marking an increase of 175.00 Cr..
- For Borrowings, as of Sep 2025, the value is 4.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 8.00 Cr. (Mar 2025) to 4.00 Cr., marking a decrease of 4.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 2,224.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2,205.00 Cr. (Mar 2025) to 2,224.00 Cr., marking an increase of 19.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 4,903.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 4,713.00 Cr. (Mar 2025) to 4,903.00 Cr., marking an increase of 190.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 1,109.00 Cr.. The value appears strong and on an upward trend. It has increased from 750.00 Cr. (Mar 2025) to 1,109.00 Cr., marking an increase of 359.00 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 291.00 Cr. (Mar 2025) to 0.00 Cr., marking a decrease of 291.00 Cr..
- For Investments, as of Sep 2025, the value is 555.00 Cr.. The value appears strong and on an upward trend. It has increased from 294.00 Cr. (Mar 2025) to 555.00 Cr., marking an increase of 261.00 Cr..
- For Other Assets, as of Sep 2025, the value is 3,240.00 Cr.. The value appears to be declining and may need further review. It has decreased from 3,377.00 Cr. (Mar 2025) to 3,240.00 Cr., marking a decrease of 137.00 Cr..
- For Total Assets, as of Sep 2025, the value is 4,903.00 Cr.. The value appears strong and on an upward trend. It has increased from 4,713.00 Cr. (Mar 2025) to 4,903.00 Cr., marking an increase of 190.00 Cr..
Notably, the Reserves (2,585.00 Cr.) exceed the Borrowings (4.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 120.00 | 145.00 | 279.00 | 324.00 | 194.00 | 376.00 | 350.00 | 369.00 | 649.00 | 656.00 | 285.00 | 607.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 185 | 156 | 185 | 175 | 191 | 148 | 180 | 177 | 157 | 165 | 173 | 165 |
| Inventory Days | 57 | 72 | 74 | 117 | 169 | 96 | 100 | 117 | 130 | 145 | 155 | 117 |
| Days Payable | 146 | 117 | 179 | 186 | 202 | 167 | 180 | 180 | 172 | 176 | 144 | 158 |
| Cash Conversion Cycle | 97 | 111 | 81 | 106 | 158 | 77 | 100 | 114 | 115 | 134 | 184 | 124 |
| Working Capital Days | 67 | 82 | 95 | 99 | 94 | 71 | 101 | 94 | 88 | 97 | 128 | 92 |
| ROCE % | 28% | 27% | 36% | 32% | 27% | 23% | 18% | 21% | 26% | 21% | 4% | 16% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| HDFC Small Cap Fund | 5,406,610 | 1.25 | 472.05 | N/A | N/A | N/A |
| DSP Small Cap Fund | 1,750,000 | 0.9 | 152.79 | 3,587,791 | 2025-12-07 00:37:56 | -51.22% |
| HDFC Hybrid Equity Fund | 920,000 | 0.33 | 80.33 | 846,062 | 2025-12-15 00:39:12 | 8.74% |
| TRUSTMF Flexi Cap Fund | 93,755 | 0.72 | 8.19 | N/A | N/A | N/A |
| Bandhan Balanced Advantage Fund | 34,622 | 0.13 | 3.02 | 50,000 | 2026-01-25 15:54:07 | -30.76% |
| Samco Multi Cap Fund | 6,921 | 0.21 | 0.6 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 33.74 | 3.53 | 37.90 | 38.71 | 25.40 |
| Diluted EPS (Rs.) | 33.74 | 3.53 | 37.90 | 38.71 | 25.40 |
| Cash EPS (Rs.) | 64.19 | 33.15 | 65.41 | 65.91 | 44.30 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 277.16 | 248.00 | 247.44 | 212.01 | 178.96 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 277.16 | 248.00 | 247.44 | 212.01 | 178.96 |
| Revenue From Operations / Share (Rs.) | 478.81 | 350.59 | 448.36 | 396.78 | 265.53 |
| PBDIT / Share (Rs.) | 72.61 | 37.98 | 75.74 | 78.89 | 53.50 |
| PBIT / Share (Rs.) | 42.17 | 8.37 | 48.24 | 51.70 | 34.61 |
| PBT / Share (Rs.) | 41.93 | 7.97 | 47.74 | 51.46 | 34.30 |
| Net Profit / Share (Rs.) | 33.74 | 3.54 | 37.91 | 38.71 | 25.41 |
| NP After MI And SOA / Share (Rs.) | 33.74 | 3.53 | 37.90 | 38.71 | 25.40 |
| PBDIT Margin (%) | 15.16 | 10.83 | 16.89 | 19.88 | 20.14 |
| PBIT Margin (%) | 8.80 | 2.38 | 10.75 | 13.03 | 13.03 |
| PBT Margin (%) | 8.75 | 2.27 | 10.64 | 12.96 | 12.91 |
| Net Profit Margin (%) | 7.04 | 1.00 | 8.45 | 9.75 | 9.56 |
| NP After MI And SOA Margin (%) | 7.04 | 1.00 | 8.45 | 9.75 | 9.56 |
| Return on Networth / Equity (%) | 12.17 | 1.42 | 15.32 | 18.26 | 14.19 |
| Return on Capital Employeed (%) | 13.88 | 3.07 | 18.28 | 22.73 | 18.10 |
| Return On Assets (%) | 6.44 | 0.78 | 7.85 | 9.33 | 8.00 |
| Total Debt / Equity (X) | 0.00 | 0.00 | 0.00 | 0.01 | 0.04 |
| Asset Turnover Ratio (%) | 0.98 | 0.75 | 0.85 | 0.93 | 0.80 |
| Current Ratio (X) | 1.81 | 1.86 | 1.65 | 1.69 | 1.84 |
| Quick Ratio (X) | 1.32 | 1.23 | 1.08 | 1.16 | 1.38 |
| Inventory Turnover Ratio (X) | 4.40 | 1.40 | 1.59 | 1.96 | 2.19 |
| Dividend Payout Ratio (NP) (%) | 18.16 | 85.75 | 16.21 | 15.49 | 7.87 |
| Dividend Payout Ratio (CP) (%) | 9.54 | 9.14 | 9.39 | 9.10 | 4.51 |
| Earning Retention Ratio (%) | 81.84 | 14.25 | 83.79 | 84.51 | 92.13 |
| Cash Earning Retention Ratio (%) | 90.46 | 90.86 | 90.61 | 90.90 | 95.49 |
| Interest Coverage Ratio (X) | 311.10 | 94.68 | 151.52 | 321.65 | 174.12 |
| Interest Coverage Ratio (Post Tax) (X) | 145.56 | 9.82 | 76.83 | 158.84 | 83.69 |
| Enterprise Value (Cr.) | 4929.40 | 2811.46 | 4234.14 | 5420.45 | 2398.75 |
| EV / Net Operating Revenue (X) | 1.14 | 0.88 | 1.05 | 1.51 | 1.00 |
| EV / EBITDA (X) | 7.52 | 8.21 | 6.20 | 7.62 | 4.97 |
| MarketCap / Net Operating Revenue (X) | 1.19 | 0.91 | 1.09 | 1.55 | 1.08 |
| Retention Ratios (%) | 81.83 | 14.24 | 83.78 | 84.50 | 92.12 |
| Price / BV (X) | 2.06 | 1.29 | 1.98 | 2.90 | 1.61 |
| Price / Net Operating Revenue (X) | 1.19 | 0.91 | 1.09 | 1.55 | 1.08 |
| EarningsYield | 0.05 | 0.01 | 0.07 | 0.06 | 0.08 |
After reviewing the key financial ratios for Sharda Cropchem Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 33.74. This value is within the healthy range. It has increased from 3.53 (Mar 24) to 33.74, marking an increase of 30.21.
- For Diluted EPS (Rs.), as of Mar 25, the value is 33.74. This value is within the healthy range. It has increased from 3.53 (Mar 24) to 33.74, marking an increase of 30.21.
- For Cash EPS (Rs.), as of Mar 25, the value is 64.19. This value is within the healthy range. It has increased from 33.15 (Mar 24) to 64.19, marking an increase of 31.04.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 277.16. It has increased from 248.00 (Mar 24) to 277.16, marking an increase of 29.16.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 277.16. It has increased from 248.00 (Mar 24) to 277.16, marking an increase of 29.16.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 478.81. It has increased from 350.59 (Mar 24) to 478.81, marking an increase of 128.22.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 72.61. This value is within the healthy range. It has increased from 37.98 (Mar 24) to 72.61, marking an increase of 34.63.
- For PBIT / Share (Rs.), as of Mar 25, the value is 42.17. This value is within the healthy range. It has increased from 8.37 (Mar 24) to 42.17, marking an increase of 33.80.
- For PBT / Share (Rs.), as of Mar 25, the value is 41.93. This value is within the healthy range. It has increased from 7.97 (Mar 24) to 41.93, marking an increase of 33.96.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 33.74. This value is within the healthy range. It has increased from 3.54 (Mar 24) to 33.74, marking an increase of 30.20.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 33.74. This value is within the healthy range. It has increased from 3.53 (Mar 24) to 33.74, marking an increase of 30.21.
- For PBDIT Margin (%), as of Mar 25, the value is 15.16. This value is within the healthy range. It has increased from 10.83 (Mar 24) to 15.16, marking an increase of 4.33.
- For PBIT Margin (%), as of Mar 25, the value is 8.80. This value is below the healthy minimum of 10. It has increased from 2.38 (Mar 24) to 8.80, marking an increase of 6.42.
- For PBT Margin (%), as of Mar 25, the value is 8.75. This value is below the healthy minimum of 10. It has increased from 2.27 (Mar 24) to 8.75, marking an increase of 6.48.
- For Net Profit Margin (%), as of Mar 25, the value is 7.04. This value is within the healthy range. It has increased from 1.00 (Mar 24) to 7.04, marking an increase of 6.04.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 7.04. This value is below the healthy minimum of 8. It has increased from 1.00 (Mar 24) to 7.04, marking an increase of 6.04.
- For Return on Networth / Equity (%), as of Mar 25, the value is 12.17. This value is below the healthy minimum of 15. It has increased from 1.42 (Mar 24) to 12.17, marking an increase of 10.75.
- For Return on Capital Employeed (%), as of Mar 25, the value is 13.88. This value is within the healthy range. It has increased from 3.07 (Mar 24) to 13.88, marking an increase of 10.81.
- For Return On Assets (%), as of Mar 25, the value is 6.44. This value is within the healthy range. It has increased from 0.78 (Mar 24) to 6.44, marking an increase of 5.66.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.98. It has increased from 0.75 (Mar 24) to 0.98, marking an increase of 0.23.
- For Current Ratio (X), as of Mar 25, the value is 1.81. This value is within the healthy range. It has decreased from 1.86 (Mar 24) to 1.81, marking a decrease of 0.05.
- For Quick Ratio (X), as of Mar 25, the value is 1.32. This value is within the healthy range. It has increased from 1.23 (Mar 24) to 1.32, marking an increase of 0.09.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.40. This value is within the healthy range. It has increased from 1.40 (Mar 24) to 4.40, marking an increase of 3.00.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 18.16. This value is below the healthy minimum of 20. It has decreased from 85.75 (Mar 24) to 18.16, marking a decrease of 67.59.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 9.54. This value is below the healthy minimum of 20. It has increased from 9.14 (Mar 24) to 9.54, marking an increase of 0.40.
- For Earning Retention Ratio (%), as of Mar 25, the value is 81.84. This value exceeds the healthy maximum of 70. It has increased from 14.25 (Mar 24) to 81.84, marking an increase of 67.59.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 90.46. This value exceeds the healthy maximum of 70. It has decreased from 90.86 (Mar 24) to 90.46, marking a decrease of 0.40.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 311.10. This value is within the healthy range. It has increased from 94.68 (Mar 24) to 311.10, marking an increase of 216.42.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 145.56. This value is within the healthy range. It has increased from 9.82 (Mar 24) to 145.56, marking an increase of 135.74.
- For Enterprise Value (Cr.), as of Mar 25, the value is 4,929.40. It has increased from 2,811.46 (Mar 24) to 4,929.40, marking an increase of 2,117.94.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.14. This value is within the healthy range. It has increased from 0.88 (Mar 24) to 1.14, marking an increase of 0.26.
- For EV / EBITDA (X), as of Mar 25, the value is 7.52. This value is within the healthy range. It has decreased from 8.21 (Mar 24) to 7.52, marking a decrease of 0.69.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.19. This value is within the healthy range. It has increased from 0.91 (Mar 24) to 1.19, marking an increase of 0.28.
- For Retention Ratios (%), as of Mar 25, the value is 81.83. This value exceeds the healthy maximum of 70. It has increased from 14.24 (Mar 24) to 81.83, marking an increase of 67.59.
- For Price / BV (X), as of Mar 25, the value is 2.06. This value is within the healthy range. It has increased from 1.29 (Mar 24) to 2.06, marking an increase of 0.77.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.19. This value is within the healthy range. It has increased from 0.91 (Mar 24) to 1.19, marking an increase of 0.28.
- For EarningsYield, as of Mar 25, the value is 0.05. This value is below the healthy minimum of 5. It has increased from 0.01 (Mar 24) to 0.05, marking an increase of 0.04.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Sharda Cropchem Ltd:
- Net Profit Margin: 7.04%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 13.88% (Industry Average ROCE: 15.21%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 12.17% (Industry Average ROE: 19.87%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 145.56
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.32
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 16.6 (Industry average Stock P/E: 28.82)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 7.04%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Agro Chemicals/Pesticides | Prime Business Park, Dashrathlal Joshi Road, Mumbai Maharashtra 400056 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Ramprakash V Bubna | Chairman & Managing Director |
| Mrs. Sharda R Bubna | Whole Time Director |
| Mr. Ashish R Bubna | Whole Time Director |
| Mr. Manish R Bubna | Whole Time Director |
| Ms. Sonal Desai | Independent Director |
| Mr. H S Upendra Kamath | Independent Director |
| Mr. Vinod Kathuria | Independent Director |
| Mr. Shalin Divatia | Independent Director |
FAQ
What is the intrinsic value of Sharda Cropchem Ltd?
Sharda Cropchem Ltd's intrinsic value (as of 27 January 2026) is ₹528.88 which is 36.28% lower the current market price of ₹830.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹7,499 Cr. market cap, FY2025-2026 high/low of ₹1,181/440, reserves of ₹2,585 Cr, and liabilities of ₹4,903 Cr.
What is the Market Cap of Sharda Cropchem Ltd?
The Market Cap of Sharda Cropchem Ltd is 7,499 Cr..
What is the current Stock Price of Sharda Cropchem Ltd as on 27 January 2026?
The current stock price of Sharda Cropchem Ltd as on 27 January 2026 is ₹830.
What is the High / Low of Sharda Cropchem Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Sharda Cropchem Ltd stocks is ₹1,181/440.
What is the Stock P/E of Sharda Cropchem Ltd?
The Stock P/E of Sharda Cropchem Ltd is 16.6.
What is the Book Value of Sharda Cropchem Ltd?
The Book Value of Sharda Cropchem Ltd is 297.
What is the Dividend Yield of Sharda Cropchem Ltd?
The Dividend Yield of Sharda Cropchem Ltd is 1.08 %.
What is the ROCE of Sharda Cropchem Ltd?
The ROCE of Sharda Cropchem Ltd is 16.5 %.
What is the ROE of Sharda Cropchem Ltd?
The ROE of Sharda Cropchem Ltd is 12.6 %.
What is the Face Value of Sharda Cropchem Ltd?
The Face Value of Sharda Cropchem Ltd is 10.0.